公开(公告)号：AU2011292040A1

公开(公告)日：2013-03-07

申请号：AU2011292040

申请日：2011-08-17

Applicant: VERTEX PHARMA

Inventor： GREEN JEREMY ,  KONG LAVAL CHAN CHUN ,  DAS SANJOY KUMAR ,  POISSON CARL ,  NANTHAKUMAR SUGANTHINI ,  WAAL NATHAN ,  LI PAN ,  RONKIN STEVEN ,  LAUFFER DAVID J ,  WILSON DEAN M

IPC: C07D333/38 ,  A61K31/381 ,  A61P31/12 ,  C07D333/40 ,  C07D409/06 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.

公开(公告)号：AU2011276526A1

公开(公告)日：2013-01-10

申请号：AU2011276526

申请日：2011-06-28

Applicant: VERTEX PHARMA

Inventor： GREEN JEREMY ,  WILSON DEAN M ,  KONG LAVAL CHAN CHUN ,  DAS SANJOY KUMAR ,  POISSON CARL ,  COURT JOHN J ,  TANG QING ,  LI PAN ,  COLLIER PHILIP N ,  WAAL NATHAN ,  LAUFFER DAVID J ,  DORSCH WARREN

IPC: C07D333/40 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4535 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  A61P31/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/08

Abstract: A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：NZ584311A

公开(公告)日：2012-03-30

申请号：NZ58431108

申请日：2008-09-30

Applicant: VERTEX PHARMA

Inventor： LAUFFER DAVID ,  LI PAN ,  WAAL NATHAN ,  MCGINTY KIRA ,  TANG QING ,  RONKIN STEVEN ,  FARMER LUC ,  SHANNON DEAN ,  JACOBS DYLAN

IPC: A61P35/00 ,  A61K31/4439 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14

Abstract: Disclosed are tetrazole compounds of formula (I), or pharmaceutically acceptable salts thereof, and methods for their preparation. R5 of the compound of formula (I) is a substituted carbon, and contributes to the compounds' decreased IC50 with respect to hydrogen-substituted analogues. Also disclosed is using compound of formula (I) for treating or lessening the severity of a proliferative disorder in a patient, wherein the proliferative disorder is metastatic cancer, glioblastoma; a gastric carcinoma, atherosclerosis or lung fibrosis or a cancer selected from colon, breast, prostate, brain, liver, pancreatic or lung cancer. Also disclosed is a method of inhibiting c-MET protein kinase activity in a biological sample in vitro comprising contacting said biological sample with a compound of formula (I).

公开(公告)号：MX2011004188A

公开(公告)日：2011-06-09

申请号：MX2011004188

申请日：2009-10-20

Applicant: VERTEX PHARMA

Inventor： TANG QING ,  LAUFFER DAVID ,  GRILLOT ANNE-LAURE ,  LI PAN ,  MCGINTY KIRA ,  WAAL NATHAN ,  RONKIN STEVEN

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D451/06 ,  F02C1/00

Abstract: La presente invención se refiere a compuestos de fórmula I útiles para la inhibición de la proteína cinasa c-Met. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la invención y método para utilizar las composiciones en el tratamiento de los trastornos proliferativos. Ver formula (I).

公开(公告)号：CA2740583A1

公开(公告)日：2010-04-29

申请号：CA2740583

申请日：2009-10-20

Applicant: VERTEX PHARMA

Inventor： LAUFFER DAVID ,  LI PAN ,  MCGINTY KIRA ,  RONKIN STEVEN ,  TANG QING ,  GRILLOT ANNE-LAURE ,  WAAL NATHAN

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D451/06

Abstract: The present invention relates to compounds of formula (I) useful in the inhibition of c- Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders.

公开(公告)号：HUE058746T2

公开(公告)日：2022-09-28

申请号：HUE19726792

申请日：2019-04-23

Applicant: MERCK PATENT GMBH ,  VERTEX PHARMA

Inventor： YU HENRY ,  CLARK MICHAEL ,  BEMIS GUY ,  BOYD MICHAEL ,  CHANDUPATLA KISHAN ,  COLLIER PHILIP ,  DENG HONGBO ,  DONG HUIJUN ,  DORSCH WARREN ,  HOOVER RUSSELL ,  JOHNSON MAC ,  KULKARNI SHASHANK ,  PENNEY MARINA ,  RONKIN STEVEN ,  TAKEMOTO DARIN ,  TANG QING ,  WAAL NATHAN ,  WANG TIANSHENG ,  LAUFFER DAVID J ,  LI PAN

IPC: C07D413/14 ,  A61P35/00 ,  C07D403/04 ,  C07D409/14 ,  C07D413/04

公开(公告)号：HUE057527T2

公开(公告)日：2022-05-28

申请号：HUE18207382

申请日：2014-03-12

Applicant: VERTEX PHARMA

Inventor： MAXWELL JOHN ,  CHARIFSON PAUL ,  TANG QING ,  RONKIN STEVEN ,  JACKSON KATRINA ,  PIERCE ALBERT ,  LAUFFER DAVID ,  LI PAN ,  GIROUX SIMON ,  XU JINWANG ,  MORRIS MARK ,  COURT JOHN ,  COTTRELL KEVIN ,  DENG HONGBO ,  WAAL NATHAN ,  GU WENXIN

IPC: C07D403/12 ,  A61P35/00 ,  C07D241/44 ,  C07D405/12 ,  C07D413/04 ,  C07D417/12

公开(公告)号：MX2012014918A

公开(公告)日：2013-04-08

申请号：MX2012014918

申请日：2011-06-28

Applicant: VERTEX PHARMA

Inventor： COURT JOHN J ,  GREEN JEREMY ,  TANG QING ,  DAS SANJOY KUMAR ,  LAUFFER DAVID J ,  KONG LAVAL CHAN CHUN ,  POISSON CARL ,  LI PAN ,  WAAL NATHAN ,  WILSON DEAN M ,  COLLIER PHILIP N ,  DORSCH WARREN

IPC: C07D333/40 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4535 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  A61P31/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/08

Abstract: Un compuesto se representa por la Fórmula Estructural (I) o su sal farmacéuticamente aceptable, en la que las variables de la Fórmula Estructural (I) son como se describe en la memoria descriptiva y las reivindicaciones. Una composición farmacéutica comprende un compuesto representado por Fórmula Estructural (I) o su sal farmacéuticamente aceptable y un portador o excipiente farmacéuticamente aceptable. Un método para tratar una infección por VHC en un sujeto comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto representado por Fórmula Estructural (I) o su sal farmacéuticamente aceptable. Un método de inhibir o reducir la actividad de polimerasa del VHC en un sujeto o en una muestra biológica in vitro comprende administrar al sujeto o a la muestra una cantidad terapéuticamente efectiva de un compuesto representado por Fórmula Estructural (I) o su sal farmacéuticamente aceptable.

公开(公告)号：NZ592569A

公开(公告)日：2012-05-25

申请号：NZ59256909

申请日：2009-10-20

Applicant: VERTEX PHARMA

Inventor： LAUFFER DAVID ,  LI PAN ,  MCGINTY KIRA ,  RONKIN STEVEN ,  TANG QING ,  GRILLOT ANNE-LAURE ,  WAAL NATHAN

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D451/06

Abstract: Disclosed are tetrazole piperazine compounds represented by general formula (I), or pharmaceutically acceptable salts thereof, wherein RA is a phenyl or 5-9 membered heteroaryl. The compounds are used to treat a proliferative disorder such as cancer.

公开(公告)号：CA2808291A1

公开(公告)日：2012-02-23

申请号：CA2808291

申请日：2011-08-17

Applicant: VERTEX PHARMA

Inventor： GREEN JEREMY ,  NANTHAKUMAR SUGANTHINI ,  WAAL NATHAN ,  LI PAN ,  RONKIN STEVEN ,  LAUFFER DAVID J ,  WILSON DEAN M ,  DAS SANJOY KUMAR ,  KONG LAVAL CHAN CHUN ,  POISSON CARL

IPC: C07D333/38 ,  A61K31/381 ,  A61P31/12 ,  C07D333/40 ,  C07D409/06 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.